Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
In addition to the CYFENDUS ® vaccine, Emergent’s anthrax franchise includes the BioThrax ® vaccine, which continues to serve a critical purpose, as well as two treatments, Anthrasil ® [Anthrax Immune ...
The newly appointed executive officers of the Miyetti Allah Cattle Breeders Association of Nigeria (MACBAN), Oyo State chapter, have been called upon to work closely with the administration of ...